Literature DB >> 820500

Amyloid fibril protein AA in Papua New Guinean amyloidosis.

R F Anders, M A Price, I S Wilkey, G Husby, F Takitaki, J B Natvig, K P McAdam.   

Abstract

In this study of protein composition of amyloid fibrils isolated from eight patients representative of the spectrum of amyloidosis found in Papua New Guinea has been investigated. All fibril preparations, including three from patients with amyloidosis secondary to lepromatous leprosy and one from an unusual juvenile case of primary amyloidosis, contained the non-immunogobulin amyloid protein, protein AA. However, only 44% of thirty-six amyloid patients had detectable levels of the protein AA-related serum component, protein SAA. Alkali-degraded material from each of the fibril preparations failed to react in double immunodiffusion test with antiserum to the amyloid-related light chain VgammaV, but evidence was found for this immunoglobulin light chain-specificity in the serum of one patient.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820500      PMCID: PMC1538517     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Unique amyloid protein subunit common to different types of amyloid fibril.

Authors:  G Husby; J B Natvig; T E Michaelsen; K Sletten; H Höst
Journal:  Nature       Date:  1973-08-10       Impact factor: 49.962

2.  Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses.

Authors:  G G Glenner; W Terry; M Harada; C Isersky; D Page
Journal:  Science       Date:  1971-06-11       Impact factor: 47.728

3.  Alternative, non-immunoglobulin origin of amyloid fibrils.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Nat New Biol       Date:  1972-08-09

4.  Amyloid fibril protein subunit, "protein AS": distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinamia.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Scand J Immunol       Date:  1973       Impact factor: 3.487

5.  N-terminal amino acid sequence of amyloid fibril protein AR, prototype of a new lambda-variable subgroup, V lambda V.

Authors:  K Sletten; G Husby; J B Natvig
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

6.  Studies of immune mechanisms in leprosy. 3. The role of cellular and humoral factors in impairment of the in vitro immune response.

Authors:  W E Bullock; P Fasal
Journal:  J Immunol       Date:  1971-04       Impact factor: 5.422

7.  Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes.

Authors:  T Godal; B Myklestad; D R Samuel; B Myrvang
Journal:  Clin Exp Immunol       Date:  1971-12       Impact factor: 4.330

8.  Variation with age and disease of an amyloid A protein-related serum component.

Authors:  C J Rosenthal; E C Franklin
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

9.  New, third class of amyloid fibril protein.

Authors:  G Husby; J B Natvig; K Sletten
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

10.  Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component.

Authors:  M Levin; M Pras; E C Franklin
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Review. Reflections on amyloidosis in Papua New Guinea.

Authors:  Per Westermark; Gunilla T Westermark
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-11-27       Impact factor: 6.237

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.